Literature DB >> 29287710

Rifampicin resistance in Staphylococcus epidermidis: molecular characterisation and fitness cost of rpoB mutations.

Yu Mi Wi1, Kerryl E Greenwood-Quaintance2, Cassandra L Brinkman2, Jean Y H Lee3, Benjamin P Howden4, Robin Patel5.   

Abstract

The molecular mechanisms and characteristics of rifampicin (RIF) resistance in Staphylococcus epidermidis are poorly characterised, even though S. epidermidis is one of the most common nosocomial pathogens associated with indwelling medical device-related infections. The aim of this study was to investigate the evolution of RIF resistance and to characterise the associated molecular mechanisms in S. epidermidis. RIF-resistant mutants from two RIF-susceptible S. epidermidis strains (RP62A and IDRL-8883) were selected through in vitro and in vivo exposure to RIF. A total of 16 colonies with an RP62A background and 63 colonies with an IDRL-8883 background were analysed for rpoB mutations. The fitness of RIF-susceptible and isogenic RIF-resistant strains was assessed using a paired competition assay and by comparing generation times. All mutations detected were in cluster I of rpoB. The following five amino acid substitutions were selected in vitro: Asp471→Asn; Asp471→Gly; Asp471→Val; Ser486→Tyr; and His481→Tyr. The following three amino acid substitutions were selected in vivo: His481→Tyr; Gln468→Lys; and Ser486→Phe. Asp471→Asn and Asp471→Gly changes were associated with susceptible minimal inhibitory concentrations (MICs). In vitro competition assays revealed that all RIF-resistant mutants other than Ser486→Tyr and Ser486→Phe had a relative fitness of <1.0. His481→Tyr mutations had their own specific fitness costs and effects on growth rate, irrespective of strain background. In conclusion, the current study presents molecular characterisations and fitness costs of several rpoB mutations in S. epidermidis.
Copyright © 2018 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  Fitness cost; Staphylococcus epidermidis; rpoB mutation

Mesh:

Substances:

Year:  2017        PMID: 29287710     DOI: 10.1016/j.ijantimicag.2017.12.019

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  9 in total

1.  In Vitro Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin against Planktonic and Biofilm States of Staphylococci Isolated from Periprosthetic Joint Infection.

Authors:  Mariana Albano; Melissa J Karau; Kerryl E Greenwood-Quaintance; Douglas R Osmon; Caitlin P Oravec; Daniel J Berry; Matthew P Abdel; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

2.  Highly Synergistic Effects of Melittin With Vancomycin and Rifampin Against Vancomycin and Rifampin Resistant Staphylococcus epidermidis.

Authors:  Rasoul Mirzaei; Mohammad Yousef Alikhani; Carla Renata Arciola; Iraj Sedighi; GholamReza Irajian; Elaheh Jamasbi; Rasoul Yousefimashouf; Kamran Pooshang Bagheri
Journal:  Front Microbiol       Date:  2022-06-23       Impact factor: 6.064

3.  Rifampin, Rifapentine, and Rifabutin Are Active against Intracellular Periprosthetic Joint Infection-Associated Staphylococcus epidermidis.

Authors:  Cody Fisher; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

4.  Effect of Short-Term Antimicrobial Therapy on the Tolerance and Antibiotic Resistance of Multidrug-Resistant Staphylococcus capitis.

Authors:  Xiao Yu; Beiwen Zheng; Feng Xiao; Ye Jin; Lihua Guo; Hao Xu; Qixia Luo; Yonghong Xiao
Journal:  Infect Drug Resist       Date:  2020-06-30       Impact factor: 4.003

5.  In-host evolution of Staphylococcus epidermidis in a pacemaker-associated endocarditis resulting in increased antibiotic tolerance.

Authors:  Vanina Dengler Haunreiter; Mathilde Boumasmoud; Nicola Häffner; Dennis Wipfli; Nadja Leimer; Carole Rachmühl; Denise Kühnert; Yvonne Achermann; Reinhard Zbinden; Stefano Benussi; Clement Vulin; Annelies S Zinkernagel
Journal:  Nat Commun       Date:  2019-03-08       Impact factor: 14.919

6.  Radical scavenging of poly(methyl methacrylate) bone cement by rifampin and clinically relevant properties of the rifampin-loaded cement.

Authors:  G A Funk; E M Menuey; K A Cole; T P Schuman; K V Kilway; T E McIff
Journal:  Bone Joint Res       Date:  2019-03-02       Impact factor: 5.853

7.  rpoB Mutations and Effects on Rifampin Resistance in Mycobacterium tuberculosis.

Authors:  Ma-Chao Li; Jie Lu; Yao Lu; Tong-Yang Xiao; Hai-Can Liu; Shi-Qiang Lin; Da Xu; Gui-Lian Li; Xiu-Qin Zhao; Zhi-Guang Liu; Li-Li Zhao; Kang-Lin Wan
Journal:  Infect Drug Resist       Date:  2021-10-05       Impact factor: 4.003

8.  Metabolomics-Driven Exploration of the Antibacterial Activity and Mechanism of 2-Methoxycinnamaldehyde.

Authors:  Chunguo Qian; Lu Jin; Longping Zhu; Yang Zhou; Jing Chen; Depo Yang; Xinjun Xu; Ping Ding; Runnan Li; Zhimin Zhao
Journal:  Front Microbiol       Date:  2022-07-07       Impact factor: 6.064

9.  Molecular Characterization of Rifampicin-Resistant Staphylococcus aureus Isolates from Retail Foods in China.

Authors:  Jiahui Huang; Feng Zhang; Jumei Zhang; Jingsha Dai; Dongli Rong; Miao Zhao; Juan Wang; Yu Ding; Moutong Chen; Liang Xue; Qihui Gu; Shi Wu; Qingping Wu
Journal:  Antibiotics (Basel)       Date:  2021-12-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.